Codiak BioSciences — Technical Presentation (November 2021)
24 slides from Codiak BioSciences's technical presentation, Nov 17, 2021
Slide 1: exoSTING First-in-Human Clinical Trial Update
EXOSTINGTM FIRST-IN-HUMAN CLINICAL TRIAL UPDATE N o v e m b e r 1 6 , 2 0 2 1 EXOSTINGTM FIRST-IN-HUMAN CLINICAL TRIAL UPDATE N o v e m b e r 1 6 , 2 0 2 1
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers These slides and the accompanying presentation contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “antic
Slide 3: exoSTING: Proof of Mechanism and Clinical Activity Signal
exoSTINGTM: Proof of Mechanism and Clinical Activity Signal Data from First-in-Human Phase 1 Study (cohorts 1-3 of 5) demonstrates: ? Tumor retention of STING agonist, no systemic exposure ? No systemic inflammatory cytokine related AEs ? Favorable safety and tolerability profile at doses tested ? I
Slide 4: The STING Pathway: Bridging Innate and Adaptive Immunity
The STING Pathway: Bridging Innate and Adaptive Immunity Step 1: Innate immune response • STING activation leads to Type I 1 Interferon (IFN) production • Leads to Chemokine production (CXCL10) 2 Step 2: APC activation and migration • IFN activates Antigen Presenting Cells (APCs) • APCs migrate via
Slide 5: STING Pathway Validation and Outstanding Challenges
STING? Pathway Validation and Outstanding Challenges Clinical validation of the STING pathway Challenges of Free STING agonists (FSAs) ?Oncolytic virus’ MOA via STING activation • Rapid efflux/leakage from tumor to circulation ?Immune surveillance STING mediated via exosomes • Systemic inflammatory
Slide 6: Novel, Differentiated STING Agonist: Preclinical Results
exoSTING™?Novel, Differentiated STING Agonist: Preclinical Results ? STING agonist targeted to tumor APC Engineered to express high levels ? Precise dosing, drug retention of PTGFRN ? Lack of systemic STING agonist exposure ? Innate and adaptive immune activation Loaded with proprietary CDN ? T-Cell
Slide 7: exoSTING First-in-human data
exoSTING™ First-in-human data PROPRIETARY INFORMATION OF CODIAK BIOSCIENCES | 7
Slide 8: exoSTING Phase 1/2 Trial: Study Design
exoSTINGTM Phase 1/2 Trial: Study Design exoSTINGTM (CDK-002) Phase 1 dose escalation Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 0.3 mcg 1 mcg 3 mcg 6 mcg 12 mcg ? ? ? Enrolling DOSE ESCALATION, “3+3” DESIGN Cycle 1 Cycle 2 Cycle 3+ Screening Dosing • Intratumoral injection in 1-3 lesions • Serial
Slide 9: Phase 1/2 Trial Strategic Objectives
exoSTING™? Phase 1/2 Trial Strategic Objectives Endpoint Measures Desired Outcome PK STING agonist Plasma levels low/absent for STING agonist Low levels of systemic inflammatory cytokines AEs SAFETY STING Pathway activation and Type I IFN St 1 Cytokines/ BLOOD activation Chemokine BIOMARKERS Nanostr
Slide 10: exoSTING Phase 1/2: Patient Demographics
exoSTINGTM Phase 1/2: Patient Demographics Cohorts 1-3 Baseline Patient Characteristics Characteristic All Patients (N = 11)* Median age, years (range) 61 (42-77) Sex, n (%) Male 5 (45.5) Female 6 (54.5) Race, n (%) Caucasian 9 (81.8) Black 1 (9.1) Asian 0 (0.0) Other/unknown 1 (9.1) ECOG PS, n (%)
Slide 11: No Systemic Exposure at Evaluated Doses
exoSTING™?No Systemic Exposure at Evaluated doses exoSTING™Free STING Agonist (FSA) Pharmacokinetics of exoSTING (C1D1) ADU-S100 o ns 100 ti 0.3 mcg tra ] 1.0 mcg e n /mL c g 10 3.0 mcg [ n con a st i m n as 1 o l LOQ 10 20 30 Meric-Bernstam et al., Clinc Cancer Res 2021 Time [Hours] Doses: 50, 100,
Slide 12: Lack of Systemic Inflammatory Cytokine Induction
exoSTING™? Lack of Systemic Inflammatory Cytokine Induction exoSTING™Free STING Agonist (FSA) Minimal <2-fold IL-6 Induction Significant IL-6 Induction ADU-S100 (800 mcg) Day1 Day 8 15 22 Cycle 1 Day 1 0.3 mcg 1 mcg 3 mcg Change Fold SITC 2018 Time (hrs) Significant induction of IL-6; IFN-â, MCP-1 S
Slide 13: Well-Tolerated at Tested Doses
exoSTING™? Well-Tolerated at Tested Doses exoSTING™Free STING agonist (MK-1454) Treatment Related Adverse Events Total N=11* Adverse event, N (%) ?1 any AE 6 (54.5) Led to discontinuation 0 (0) Grade ? 3 0 (0) Led to death 0 (0) AEs ? 10% of patients Fatigue 2 (18.2) Tumor pain 2 (18.2) *all patient
Slide 14: Dose Dependent STING Activation
exoSTING™?Dose Dependent STING Activation: Confirmation of Step 1 1 Innate immune exoSTING™Free STING Agonist (FSA) response Dose Dependent CXCL10 mRNA induction MK-1454 IP-10/ CXCL10 Baseline from ge Chan Fold 0.3 1.0 3.0 Abstract, ESMO 2019 Dose [mcg] STING pathway activation at doses Dose expansi
Slide 15: Dose Dependent Induction of Type I Interferon Signaling in Peripheral Blood
exoSTING™? Dose Dependent Induction of Type I Interferon Signaling in Peripheral Blood: Confirmation of Step 2 2 Activation/Migration of the APC into peripheral blood Pre 6hr 24hr 3.0 mcg 1.0 mcg 0.3 mcg Cycle 1 Pre 6hr 24hr • Induction of Interferon Stimulated Genes (ISGs) • Induction of APC activa
Slide 16: CD8 T Cell Infiltration and Activation
exoSTING™? CD8 T Cell Infiltration and Activation: Confirmation of Step 3 3 Adaptive immune response • Adaptive immune response with 3 and 11- fold Before After (Week 6) increase in CD8 T cells in 2/2 patients with paired DAPI biopsies CD8 PD-L1 • Recruit stem-like progenitor effector CD8+/TCF7+ TCF
Slide 17: Interferon Response in Blood Cells May Correlate with Clinical Antitumor Signal
exoSTING™? Interferon Response in Blood Cells May Correlate with Clinical Antitumor Signal 100 Pre 6hr 24 hr # 90 Chondrosarcoma Parotid Gland Ca cSCC (Case #1) (Case #2) (Case #3) 80 70 # Signature 60 ISG 50 of 40 30 * Induction 20 Fold 10 0 Cohort 1 (0.3 mcg) Cohort 2 (1 mcg) Cohort 3 (3 mcg) * On
Slide 18: Case Study #1, Cohort 1 (0.3 mcg) Shows Immune Activation
exoSTING™? Case Study #1, Cohort 1 (0.3 mcg) Shows Immune Activation 57 yo male with Chondrosarcoma Progression on 2 lines of therapy including combination PD-1 inhibitor / chemotherapy Chondrosarcoma Treatment at lowest dose exoSTINGTM in 100 patient with “cold” tumor resulted in: 80 FROM • Stable
Slide 19: Case Study #2, Cohort 2 (1 mcg) Clinical Signal in Non-injected Distal Lesion
exoSTING™? Case Study #2, Cohort 2 (1 mcg) Clinical Signal in Non-injected Distal Lesion 42 yo female with Parotid Gland Carcinoma • On study drug for >7 months in heavily pretreated patient Progression on 4 lines of chemotherapy • 74% decrease in non-injected tumor Parotid Gland Carcinoma (distal e
Slide 20: Case Study #3, Cohort 3 (3 mcg) Clinical Signal in Injected Lesion
exoSTING™? Case Study #3, Cohort 3 (3 mcg) Clinical Signal in Injected Lesion 75 yo male with Cutaneous Squamous Cell Carcinoma (cSCC) Progression on 3 lines of therapy including PD-1 inhibitor cSCC 40 • 77% decrease in injected tumor #2 20% 20 Baseline increase • 11-fold increase in T cell influx i
Slide 21: exoSTING: Proof of Mechanism and Clinical Activity Signal
exoSTINGTM: Proof of Mechanism and Clinical Activity Signal Data from First-in-Human Phase 1 Study (cohorts 1-3 of 5) demonstrates: ? Tumor retention of STING agonist, no systemic exposure ? No systemic inflammatory cytokine related AEs ? Favorable safety and tolerability profile at doses tested ? I
Slide 22: exoSTING Future Direction
exoSTINGTM?Future Direction • Complete enrollment in cohorts 4 and 5 in 1H’22 • Determine Recommended Phase 2 Dose in 1H’22 • Assess antitumor activity from dose escalation in 1H’22 • Plan to submit data at scientific/medical conference in 1H’22 • Opportunities for single agent and combination strat
Slide 23: Clinical Results Highlight Novel, Differentiated Profile
exoSTING™?Clinical Results Highlight Novel, Differentiated Profile ? Encouraging human clinical data supports advancement of exoSTINGTM program ? exoSTINGTM is a potent and active molecule with a wide therapeutic index ? Multiple opportunities as both single agent and in combination ? Encouraging in
Slide 24: Codiak
coBiak
Codiak BioSciences — Technical Presentation (November 2021) on 6ix